摘要
[目的]探讨盐酸埃克替尼治疗晚期非小细胞肺癌患者的疗效和安全性。[方法]对190例单药盐酸埃克替尼治疗的患者进行随访,中位随访时间为21个月,记录有效性及不良反应数据。[结果]全组中位PFS为8.1个月（95%CI：6.4-9.8个月）,中位OS为14.1个月（95%CI：11.5-16.7个月）,DCR为71.6%（136/190）,ORR为35.3%（67/190）。女性、不吸烟患者的PFS优于男性,吸烟患者。而PS评分低及埃克替尼用于二线及以上治疗者表现出更长的PFS及OS。治疗相关不良反应主要为皮疹（38.9%）、腹泻（13.7%）、转氨酶升高（11.1%）及上腹部不适（7.9%）,1例出现肺间质样改变。[结论]埃克替尼治疗晚期非小细胞肺癌具有较好的疗效及安全性。
[Purpose] To investigate the efficacy and toxicity of icotinib hydrochloride in the treatment for patients with advanced non-small cell lung cancer（NSCLC）. [Methods] One hundred and ninety cases with advanced NSCLC treated with icotinib hydrochloride were enrolled,median followup period was 21 months,data of efficacy and toxicity were recorded. [Results] The median progression-free survival（PFS） time was 8.1 months（95% CI：6.4 -9.8months,the median overall survival（OS） time was 14.1 months（95% CI：11.5 -16.7 months）.The disease control rate was 71.6%（136/190）,the objective response rate was 35.3%（67/190）. The median PFS of female with non-smoking was better than that of male with smoking. Patients with lower PS and treated with icotinib as multiline treatments have a longer PFS and OS. The major toxicities were rash（38.9%）,diarrhea（13.7%）,transaminase elevation（11.1%） and epigastric discomfort（7.9%）,and only 1 case had pulmonary intestinal change. [Conclusion] Icotinib hydrochloride is effective and safe for Chinese patients with advanced NSCLC.
出处
《中国肿瘤》
CAS
2015年第2期149-154,共6页
China Cancer
